在地幔细胞淋巴瘤中,PRMT5支持多种瘤性途径
Shelby L Sloan1,2, Fiona Brown1, Mackenzie Long1,2
1Division of Hematology, Department of Internal Medicine, College of Medicine, The Ohio State University, Columbus, OH.
Blood
|June 2, 2023
概括
使用PRT-382准蛋白质氨酸甲基转移酶5 (PRMT5) 对地幔细胞淋巴瘤 (MCL) 有希望. 这种方法可以阻止癌症的生长,并诱导细胞死亡,为复发性/耐药性MCL患者提供新的希望.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 表观遗传学 在表观遗传学中,表观遗传学是指表观遗传学.
背景情况:
- 薄膜细胞淋巴瘤 (MCL) 是一种具有侵略性的B细胞癌,预后不佳,特别是在治疗失败后.
- 蛋白质氨酸甲基转移酶5 (PRMT5) 在MCL中过度表达,并通过表观遗传和翻译后修改驱动癌症的进展.
- 目前对复发性/耐药性MCL的治疗选择有限,需要新的治疗策略.
研究的目的:
- 为了研究PRMT5抑制在地幔细胞淋巴瘤 (MCL) 的抗瘤活性.
- 阐明PRMT5在MCL病变发生和针对性治疗的反应中的作用背后的分子机制.
- 为了确定潜在的生物标志物来预测MCL的治疗反应.
主要方法:
- 利用集成的转录组学 in vitro 和 in vivo MCL 模型.
- 使用了PRMT5,PRT-382.2的选择性小分子抑制剂.
- 分析了转录重编程,细胞循环调节,细胞亡和信号通路调节.
主要成果:
- 在MCL模型中,PRMT5抑制与PRT-382诱导的细胞生长停止和细胞亡.
- 在患者衍生的MCL异种移植中观察到治疗益处.
- 抑制PRMT5恢复了细胞周期控制,诱导了细胞亡,并调节了B细胞受体信号通路.
结论:
- 药理上抑制PRMT5是一种有前途的治疗策略,用于复发性/耐药性MCL.
- 生物标志物如MTAP/CDKN2A删除和野生型TP53可以预测对PRMT5抑制的有利反应.
- 针对PRMT5的向要求对MCL治疗进行进一步的临床研究.
相关概念视频
mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
Abnormal Proliferation
4.6K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.6K
Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Interactions Between Signaling Pathways
6.3K
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.3K
PI3K/mTOR/AKT Signaling Pathway
3.7K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.7K


